Danila Branca
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Danila Branca.
Bioorganic & Medicinal Chemistry Letters | 2008
Ester Muraglia; Sergio Altamura; Danila Branca; Ottavia Cecchetti; Federica Ferrigno; Maria Vittoria Orsale; Maria Cecilia Palumbi; Michael Rowley; Rita Scarpelli; Christian Steinkühler; Philip Jones
Trifluoroacetylthiophene carboxamides have recently been reported to be class II HDAC inhibitors, with moderate selectivity. Exploration of replacements for the carboxamide with bioisosteric pentatomic heteroaromatic like 1,3,4-oxadiazoles, 1,2,4-oxadiazoles and 1,3-thiazoles, led to the discovery that 2-trifluoroacetylthiophene 1,3,4-oxadiazole derivatives are very potent low nanomolar HDAC4 inhibitors, highly selective over class I HDACs (HDAC 1 and 3), and moderately stable in HCT116 cell culture.
Bioorganic & Medicinal Chemistry Letters | 2009
Federica Orvieto; Danila Branca; Claudia Giomini; Philip Jones; Uwe Koch; Jesus M. Ontoria; Maria Cecilia Palumbi; Michael Rowley; Carlo Toniatti; Ester Muraglia
A novel series of pyrazolo[1,5-a]quinazolin-5(4H)-one derivatives proved to be a potent class of PARP-1 inhibitors. An extensive SAR around the 3-position of pyrazole in the scaffold led to the discovery of amides derivatives as low nanomolar PARP-1 inhibitors.
Bioorganic & Medicinal Chemistry Letters | 2009
Gabriella Dessole; Danila Branca; Federica Ferrigno; Olaf Kinzel; Ester Muraglia; Maria Cecilia Palumbi; Michael Rowley; Sergio Serafini; Christian Steinkühler; Philip Jones
We report the synthesis and biological evaluation of N-[(1-aryl-1H-indazol-5-yl)methyl]amide derivatives as Smoothened antagonists and inhibitors of the Hedgehog pathway. Identification of the lead structure 1 by HTS, followed by SAR study on the amide and aryl portions led to the discovery of antagonists with nanomolar activity.
Bioorganic & Medicinal Chemistry Letters | 2011
Ester Muraglia; Jesus M. Ontoria; Danila Branca; Gabriella Dessole; Alberto Bresciani; Massimiliano Fonsi; Claudio Giuliano; Laura Llauger Bufi; Edith Monteagudo; Maria Cecilia Palumbi; Caterina Torrisi; Michael Rowley; Christian Steinkühler; Philip Jones
Smoothened (Smo) antagonists are emerging as new therapies for the treatment of neoplasias with aberrantly reactivated hedgehog (Hh) signaling pathway. A novel series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as smoothened antagonists was recently described, herein the series has been further optimized through the incorporation of a basic amine into the urea. This development resulted in identification of some exceptionally potent smoothened antagonists with low serum shifts, however, reductive ring opening on the 1,2,4-oxadiazole in rats limits the applicability of these compounds in in vivo studies.
Bioorganic & Medicinal Chemistry Letters | 2009
Danila Branca; Mauro Cerretani; Philip Jones; Uwe Koch; Federica Orvieto; Maria Cecilia Palumbi; Michael Rowley; Carlo Toniatti; Ester Muraglia
PARP inhibitors have been demonstrated to retard intracellular DNA repair and therefore sensitize tumor cells to cytotoxic agents or ionizing radiation. We report the identification of a novel class of PARP1 inhibitors, containing a pyrrolo moiety fused to a dihydroisoquinolinone, derived from virtual screening of the proprietary collection. SAR exploration around the nitrogen of the aminoethyl appendage chain of 1 led to compounds that displayed low nanomolar activity in a PARP1 enzymatic assay.
Bioorganic & Medicinal Chemistry Letters | 2010
Giovanna Pescatore; Danila Branca; Fabrizio Fiore; Olaf Kinzel; Laura Llauger Bufi; Ester Muraglia; Federica Orvieto; Michael Rowley; Carlo Toniatti; Caterina Torrisi; Philip Jones
Herein we describe the discovery of a novel series of pyrrolo[1,2-a]pyrazin-1(2H)-one PARP inhibitors. Optimization led to compounds that display excellent PARP-1 enzyme potency and inhibit the proliferation of BRCA deficient cells in the low double-digit nanomolar range showing excellent selectivity over BRCA proficient cancer cells.
Bioorganic & Medicinal Chemistry Letters | 2010
Federica Ferrigno; Danila Branca; Olaf Kinzel; Samuele Lillini; Laura Llauger Bufi; Edith Monteagudo; Ester Muraglia; Michael Rowley; Carsten Schultz-Fademrecht; Carlo Toniatti; Caterina Torrisi; Philip Jones
We describe an extensive SAR study in the 6-[4-fluoro-3-(substituted)benzyl]-4,5-dimethylpyridazin-3(2H)-one series which led to the identification of potent PARP-1 inhibitors, capable of inhibiting the proliferation of BRCA-1 deficient cancer cells in the low nanomolar range, and displaying >100-fold selectivity over the BRCA wild type counterparts. The series of compounds was devoid of hERG channel activity, and CYP inhibition and induction liabilities. Several analogs were stable in rat and human liver microsomes and displayed moderate rat clearance, with urinary excretion of parent as the major route of elimination.
Archive | 2007
Julia K. Boueres; Danila Branca; Federica Ferrigno; Philip Jones; Ester Muraglia; Jesus M. Ontoria; Federica Orvieto; Rita Scarpelli; Carsten Schultz-Fademrecht
Archive | 2008
Danila Branca; Gabriella Dessole; Federica Ferrigno; Philip Jones; Olaf Kinzel; Samuele Lillini; Ester Muraglia; Giovanna Pescatore; Carsten Schultz-Fademrecht
Archive | 2009
Danila Branca; Federica Ferrigno; José Ignacio Martı́n Hernando; Philip Jones; Olaf Kinzel; Savina Malancona; Ester Muraglia; Maria Cecilia Palumbi; Giovanna Pescatore; Rita Scarpelli